Use of a combination of ethinyloestradiol and chlormadinone acetate to produce a pharmaceutical preparation

1 . Use of a combination of ethinyloestradiol and chlormadinone acetate to produce a pharmaceutical preparation

for the treatment of androgen-induced disorders and

for hormone replacement therapy and

for the treatment of dysmenorrhoea and

for stabilising the menstrual cycle and

for the treatment of menstrual cycle-dependent complaints and

for contraception

simultaneously in women.

2 . Use according to claim 1 for administration to women over 35, preferably women in the pre- or perimenopause.

3 . Use according to claim 1 , characterised in that the combination consists of 5 to 50 μg of ethinyloestradiol and 1 to 5 mg of chlormadinone acetate.

4 . Use according to claim 1 , characterised in that the combination consists of 5 to 30 μg of ethinyloestradiol and 1 to 5 mg of chlormadinone acetate.

5 . Use according to claim 4 , characterised in that the combination consists of 15 μg, 20 μg or 30 μg of ethinyloestradiol and 1, 2, 3, 4 or 5 mg of chlormadinone acetate.

6 . Use according to claim 1 , characterised in that the pharmaceutical preparation is prepared in the form of at least 21 hormone-containing daily units for uninterrupted administration, optionally in combination with 7 to 3 hormone-free daily units.

7 . Use according to claim 6 , characterised in that the pharmaceutical preparation is prepared in the form of hormone-containing daily units for uninterrupted administration over several years, preferably up to 2 years, particularly preferably up to 1 year, optionally in combination with 7 to 3 hormone-free daily units.

8 . Use according to claim 6 , characterised in that the pharmaceutical preparation is prepared in the form of 77 to 193 hormone-containing daily units optionally in combination with 7 to 3 hormone-free daily units.

9 . Use according to claim 6 , characterised in that the pharmaceutical preparation is prepared in the form of 42 to 52 hormone-containing daily units optionally in combination with 7 to 3 hormone-free daily units.

10 . Use according to claim 6 , characterised in that the pharmaceutical preparation is prepared in the form of 21 to 25 hormone-containing daily units optionally in combination with 7 to 3 hormone-free daily units.

11 . Use according to claim 1 , characterised in that, with regard to quantities, the pharmaceutical preparation comprises in each of the hormone-containing daily units the same combination of ethinyloestradiol and chlormadinone acetate.

12 . Use according to claim 1 for the treatment of the androgen-induced disorders acne, hirsutism, androgenetic alopecia, seborrhoea.

13 . Use according to claim 1 for hormone replacement therapy to treat vasomotor disorders, in particular to treat hot flushes, sweating, insomnia.

14 . Use according to claim 1 for the treatment of the menstrual cycle-dependent complaint premenstrual syndrome, in particular headache and/or migraine.